Cytek Biosciences, Inc. (CTKB) is a Fremont, California-based cell analysis company that sells spectral flow cytometry instruments, reagents and software — including its Aurora and Northern Lights platforms — to academic, pharmaceutical and contract research customers worldwide. Shares traded at $6.26 at midday, up $0.34, or 5.74%, from the previous session's close of $5.92, confirming an upward move. No verified news catalyst was found for the advance; the gain appears to be a continuation of the post-earnings bid that has lifted the stock from its Nov. 5 low near $5.30.
No verified news or fundamental catalyst found for the session. The only company release ahead of the move was a Nov. 18 announcement that management will meet investors at the Evercore Healthcare Conference on Dec. 1 and the Piper Sandler Healthcare Conference on Dec. 2 — a routine calendar item with no change to outlook, and too small on its own to justify a 5.7% move. The action is instead consistent with a momentum-driven continuation: the stock has now recovered nearly all of its 8.2% post-earnings decline on Nov. 5 and is trading just below its 52-week high of $6.34, a level it last touched on Oct. 29. With roughly 1.3 million shares changing hands on an average day against a float of about 117 million shares, modest incremental demand can move the quote meaningfully.
The larger driver remains the third-quarter report delivered on Nov. 4. Cytek posted revenue of $53.23 million against consensus near $53.05 million, a loss of $0.05 per share versus an expected $0.07 loss, and a gross margin near 59%, helped by the shift of manufacturing to Singapore. Management narrowed full-year revenue guidance to $208 million–$211 million and pointed to near-breakeven adjusted EBITDA. Stephens subsequently raised its target to $7 from $6 with an Overweight rating, and Piper Sandler carries a $7.50 target, both well above the current quote. That gap has kept dip-buyers active on pullbacks, and the Nov. 19 session reflects that pattern — a pre-market gain of roughly 6% before the opening bell set the tone for the day.
The move stood apart from large-capitalization life-science tools peers such as TMO and ILMN, which showed no comparable catalyst, reinforcing that the buying was specific to this small-cap name. Turnover has run in a range of roughly 0.6 million to 1.1 million shares per session over the past two weeks, below the 30-day average near 1.3 million, so the advance has come on moderate rather than heavy volume. Technically, the stock is holding comfortably above its 50-day and 200-day moving averages and has rebuilt a base above $5.60 after the November earnings shakeout. The immediate resistance is the $6.34 October high, with support near $5.90–$5.92.
The score runs from 0 — no meaningful news and a move that is normal for the stock — to 100, meaning transformative news and an extreme, rare price move. Cytek's score is 12 out of 100. The news component is minimal: no verified release, filing or analyst action accompanied the session, only a routine conference notice. The price component is also restrained: the 5.74% gain is about 2.2 times the stock's average absolute daily move of 2.55% over the past 60 sessions, and moves of that size or larger occurred seven times in that window. A modest catalyst paired with a moderately unusual move produces a low score.
Attention turns to the Dec. 1–2 investor conferences, where management may update commentary on U.S. academic and government demand, EMEA stabilization and Aurora Evo adoption. The fourth quarter is seasonally the company's strongest, and the narrowed $208 million–$211 million guidance range leaves little room for execution error, particularly with China revenue still contracting year over year. Analysts remain split, with targets ranging from $5 to $7.50 and a consensus near $6.50, so rating changes could swing sentiment quickly. Investors should also weigh continued GAAP losses, thin liquidity and the stock's sensitivity to research-funding headlines, all of which argue for expecting volatility rather than a smooth re-rating.
Tickeron's Trending AI Robots page highlights the automated strategies delivering the strongest results under present market conditions. The platform hosts hundreds of AI trading bots spanning thousands of tickers, and the trending section curates only the top performers rather than listing the full inventory. Bots differ widely by strategy logic, holding period, risk profile, performance metrics and the symbols they trade, so results vary considerably. Reviewing the current leaders is a practical way to see which approaches are working now and to evaluate them against your own objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CTKB broke above its upper Bollinger Band on November 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 34 similar instances where the stock broke above the upper band. In 29 of the 34 cases the stock fell afterwards. This puts the odds of success at 85%.
The 10-day RSI Indicator for CTKB moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 16 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTKB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on CTKB as a result. In 56 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for CTKB just turned positive on November 19, 2026. Looking at past instances where CTKB's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Following a +10.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTKB advanced for three days, in 231 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 113 of 149 cases where CTKB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.354) is normal, around the industry mean (4.142). P/E Ratio (-9.254) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.064) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CTKB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTKB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices